Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIK-B2: Alpelisib + Trastuzumab + Pertuzumab in HER2+ Advanced Breast Cancer with PIK3CA Mutation
NCT04208178Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2020
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of alpelisib in breast cancer, sponsored by Novartis. Started Jul 2020; status: active, not recruiting.
02
Drugs
alpelisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04208178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04208178.